We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Read MoreHide Full Article
Key Takeaways
TNGX rose 53% after reporting encouraging early data for vopimetostat combinations in pancreatic cancer.
TNGX's vopimetostat-daraxonrasib arm posted 92% ORR, 100% DCR and 90% six-month PFS.
TNGX plans late-stage development and is expanding vopimetostat studies through new collaborations.
Shares of Tango Therapeutics (TNGX - Free Report) surged 53% on Monday after the company reported encouraging initial data from an ongoing phase I/II study evaluating combination treatments involving its investigational drug, vopimetostat.
The study is assessing vopimetostat plus one of Revolution Medicines’ (RVMD - Free Report) experimental RAS inhibitors — daraxonrasib or zoldonrasib — in previously treated patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC).
The strongest results were reported from the vopimetostat-daraxonrasib arm. Among 12 evaluable patients, the combination achieved an objective response rate (ORR) of 92%, with a disease control rate (DCR) of 100% and a six-month progression-free survival (PFS) rate of 90%. In contrast, the vopimetostat-zoldonrasib combination achieved a 52% ORR across 27 evaluable patients, a DCR of 96% and a six-month PFS rate of 74%. Both combinations were generally well tolerated.
The data drew significant attention from investors and analysts, many of whom were particularly impressed by the vopimetostat-daraxonrasib results. Investors also welcomed the company's decision to advance this combination into late-stage development for first-line MTAP-deleted pancreatic cancer.
Management believes the findings support the broader strategy of combining PRMT5 inhibition with RAS-targeted therapies and reinforce the potential for a chemotherapy-free treatment option in patients with MTAP-deleted pancreatic cancer.
TNGX Stock’s Price Performance
Year to date, the company’s shares have skyrocketed 249% against the industry’s 3% fall.
Image Source: Zacks Investment Research
More on TNGX’s Vopimetostat
The drug is a selective PRMT5 inhibitor designed to target cancers harboring MTAP deletions, a genetic alteration found across multiple tumor types, including pancreatic cancer. Apart from the above study, vopimetostat is also being tested as a monotherapy in a phase I/II study across MTAP-deleted solid tumors. Data from this study is expected later this year.
In March, Tango Therapeutics entered into a clinical trial collaboration and supply agreement with Erasca (ERAS - Free Report) . Under the agreement, the companies will evaluate vopimetostat in combination with ERAS' pan-RAS molecular glue, ERAS-0015, in patients with MTAP-deleted RAS-mutant cancers. Tango plans to initiate a phase I/II study before year-end, further expanding the development opportunities for vopimetostat.
View the Zacks #1 Rank List
Image: Bigstock
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Key Takeaways
Shares of Tango Therapeutics (TNGX - Free Report) surged 53% on Monday after the company reported encouraging initial data from an ongoing phase I/II study evaluating combination treatments involving its investigational drug, vopimetostat.
The study is assessing vopimetostat plus one of Revolution Medicines’ (RVMD - Free Report) experimental RAS inhibitors — daraxonrasib or zoldonrasib — in previously treated patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC).
The strongest results were reported from the vopimetostat-daraxonrasib arm. Among 12 evaluable patients, the combination achieved an objective response rate (ORR) of 92%, with a disease control rate (DCR) of 100% and a six-month progression-free survival (PFS) rate of 90%. In contrast, the vopimetostat-zoldonrasib combination achieved a 52% ORR across 27 evaluable patients, a DCR of 96% and a six-month PFS rate of 74%. Both combinations were generally well tolerated.
The data drew significant attention from investors and analysts, many of whom were particularly impressed by the vopimetostat-daraxonrasib results. Investors also welcomed the company's decision to advance this combination into late-stage development for first-line MTAP-deleted pancreatic cancer.
Management believes the findings support the broader strategy of combining PRMT5 inhibition with RAS-targeted therapies and reinforce the potential for a chemotherapy-free treatment option in patients with MTAP-deleted pancreatic cancer.
TNGX Stock’s Price Performance
Year to date, the company’s shares have skyrocketed 249% against the industry’s 3% fall.
Image Source: Zacks Investment Research
More on TNGX’s Vopimetostat
The drug is a selective PRMT5 inhibitor designed to target cancers harboring MTAP deletions, a genetic alteration found across multiple tumor types, including pancreatic cancer. Apart from the above study, vopimetostat is also being tested as a monotherapy in a phase I/II study across MTAP-deleted solid tumors. Data from this study is expected later this year.
In March, Tango Therapeutics entered into a clinical trial collaboration and supply agreement with Erasca (ERAS - Free Report) . Under the agreement, the companies will evaluate vopimetostat in combination with ERAS' pan-RAS molecular glue, ERAS-0015, in patients with MTAP-deleted RAS-mutant cancers. Tango plans to initiate a phase I/II study before year-end, further expanding the development opportunities for vopimetostat.
Tango Therapeutics, Inc. Price
Tango Therapeutics, Inc. price | Tango Therapeutics, Inc. Quote
TNGX’s Zacks Rank
Tango Therapeutics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.